The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Peptides for Highly Efficient Cancer Immunotherapy


Stanford Reference:

03-078


Abstract


This simple, patented vaccination strategy is designed to improve cancer immunotherapy by producing a maximally effective T cell response in patients. The approach uses both a native agonist peptide and an analog peptide to elicit high recognition efficiency (RE) T-cells that are truly cytolytic for a target cell. This is an advantage over standard vaccination methods (with high doses of agonist peptides only) which produce predominantly ineffective, low RE T-cells.

Applications


  • Cancer immunotherapy - activate cytolytic T cells for therapeutic and prophylactic vaccines.

Advantages


  • High efficiency vaccination - holds the potential to dramatically improve the clinical efficacy of therapeutic as well as preventive vaccination.

Publications



Related Web Links



Innovators & Portfolio


  • Peter Lee   
  • Tor Stuge   

Patent Status



Date Released

 9/25/2014
 

Licensing Contact


Ximena Ares, Licensing Associate
650-724-0960 (Direct)
Login to Request Information

[-] Map/Timeline

92-045 Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
97-184 Monoclonal Antibody to Human CD81

more technologies

Related Keywords


immunotherapy   tumorreactive T- cells   cancer immunotherapy   cancer vaccine   anti-tumor   therapeutic: immunotherapy   t cell therapy   T cell   peptides   oncolytic immunotherapy   tumor immunology   tumor vaccine   
 

   

  

Also of Interest...
92-045 Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
97-184 Monoclonal Antibody to Human CD81

Recently Viewed...
S03-078 Peptides for Highly Efficient Cancer Immunotherapy